Valiant Laboratories Limited is an India-based pharmaceutical ingredient manufacturing company. The Company is focused on manufacturing a Paracetamol active pharmaceutical ingredient (API)/bulk drug. It has several applications in the treatment of conditions such as headache, muscle ache, arthritis, backache, toothache, cold and fever. It is also used in the management of severe pain such as post-surgical and cancer pain. It operates a single-location manufacturing facility on the Tarapur industrial estate.

Employees

Sector

Specialty Chemicals

More about the company

Quotes

Date	Price	Change	Volume
06/11/26	₹116.10	-1.99%	3,573
05/11/26	₹118.46	-1.99%	5,041
04/11/26	₹120.87	-1.99%	10,754
03/11/26	₹123.33	-1.99%	9,901
02/11/26	₹125.84	-1.99%	77,172

End-of-day quote NSE India S.E.

More quotes

End-of-day quote NSE India S.E. 06/11/2026			5-day change	1st Jan Change
116.10 ^INR	-1.99%		-9.58%	+65.86%

11-02	Valiant Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026	CI
10-06	8,694,345 Equity Shares of Valiant Laboratories Limited are subject to a Lock-Up Agreement Ending on 6-OCT-2026.	CI

Market Cap	6.31B 67.08M 60.16M 54.98M 50.19M 94.57M 97.55M 663M 264M 3.36B 252M 246M 10.62B	P/E 2025	-150x	P/E 2026	-79.4x
Enterprise Value	6.44B 68.47M 61.41M 56.12M 51.23M 96.53M 99.57M 676M 270M 3.43B 257M 251M 10.84B	EV / Sales 2025	2.83x	EV / Sales 2026	1.24x
Free-Float	23.22%	Yield 2025 *	-	Yield 2026	-

Markets		Quality
NSE India S.E.	VALIANTLAB	End-of-day quote
Bombay S.E.	VALIANTLAB	Delayed

11-02	Valiant Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026	CI
10-06	8,694,345 Equity Shares of Valiant Laboratories Limited are subject to a Lock-Up Agreement Ending on 6-OCT-2026.	CI
09-30	Valiant Laboratories Limited Announces Change in Registered Office Address	CI
08-11	Valiant Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
08-10	Valiant Laboratories Limited Approves the Opening of New Corporate Office	CI
05-20	Valiant Organics Limited agreed to acquire 34.26% stake in Valiant Laboratories Limited from Dhanvallabh Ventures LLP.	CI
05-14	Valiant Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
04-23	Valiant Laboratories Limited Announces Resignation of Bhanudas D. Patil as Q.C Manager, Senior Management Personnel, Effective April 22, 2026	CI
02-11	Valiant Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
01-15	Valiant Laboratories Ltd receives notice for total tax demand of approx. 125.3 million rupees	RE
11-12	Valiant Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
11-07	Valiant Laboratories Arm Begins Commercial Operations at New Unit in Gujarat, India; Shares Up 4%	MT
25/09/25	Valiant Laboratories Limited Approves Change in Designation of Paresh Shah from Executive Director to Whole-Time Director, Effective September 25, 2025	CI

Valiant Laboratories Limited Stock

Stocks

VALIANTLAB

INE0JWS01017

Specialty Chemicals

Valuation: Valiant Laboratories Limited

Chart: Valiant Laboratories Limited

Latest news: Valiant Laboratories Limited

Quotes and Performance

Price Extremes

Managers and Directors: Valiant Laboratories Limited

Other Specialty Chemicals

Financials

Company Profile

Quotes

1 day	-1.99%
1 week	-9.58%
Current month	-9.58%
1 month	-6.65%
3 months	+88.72%
6 months	+47.99%
Current year	+65.86%

1 week	116.1	128.6
1 month	113	141.38
Current year	49.51	141.38
1 year	49.51	141.38
3 years	49.51	214.95
5 years	49.51	214.95
10 years	49.51	214.95

Manager	Title	Age	Since
Santosh Vora CEO	Chief Executive Officer	32	21/08/2021
Paresh Shah DFI	Director of Finance/CFO	66	16/08/2021
Akshay Dnyaneshwar Gangurde CMP	Compliance Officer	-	09/07/2025

Director	Title	Age	Since
Santosh Vora BRD	Director/Board Member	32	21/08/2021
Sonal Amit Vira BRD	Director/Board Member	44	16/02/2022
Paresh Shah BRD	Director/Board Member	66	16/08/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VALIANT LABORATORIES LIMITED	-1.99%	-9.58%	+43.05%	-37.96%	67.08M
ECOLAB INC.	-1.68%	-0.76%	+18.82%	+72.34%	84.33B
GIVAUDAN SA	-1.24%	+2.04%	+22.29%	+33.44%	45.66B
SIKA AG	-1.85%	+3.43%	+21.60%	-17.67%	36.26B
HENKEL AG & CO. KGAA	-0.88%	+3.84%	+16.20%	+22.74%	35.21B
NOVONESIS A/S	-4.15%	-0.43%	+10.84%	+36.05%	31.96B
FUJIFILM HOLDINGS CORPORATION	-5.90%	-6.14%	-3.58%	+14.30%	24.83B
EMS-CHEMIE HOLDING AG	-1.28%	+0.65%	+57.86%	+40.02%	24.21B
DUPONT DE NEMOURS, INC.	+1.10%	+4.62%	+24.75%	-29.77%	19.42B
SOCIEDAD QUÍMICA Y MINERA DE CHILE S.A.	+2.06%	+5.25%	+24.31%	+19.93%	16.43B
Average	-1.58%	+0.48%	+23.61%	+15.34%	31.84B
Weighted average by Cap.	-1.73%	+0.99%	+20.42%	+31.44%

	2025	2026
Net sales	1.33B 14.19M 12.73M 11.63M 10.62M 20M 20.63M 140M 55.9M 712M 53.26M 52.12M 2.25B	2.37B 25.26M 22.66M 20.71M 18.9M 35.61M 36.74M 250M 99.52M 1.27B 94.82M 92.79M 4B
Net income	-22.01M -234K -210K -192K -175K -330K -341K -2.31M -923K -11.75M -879K -860K -37.08M	-32.68M -348K -312K -285K -260K -490K -506K -3.43M -1.37M -17.44M -1.3M -1.28M -55.05M
Net Debt	453M 4.82M 4.32M 3.95M 3.61M 6.79M 7.01M 47.6M 18.98M 242M 18.08M 17.7M 763M	131M 1.39M 1.25M 1.14M 1.04M 1.96M 2.02M 13.73M 5.47M 69.7M 5.22M 5.1M 220M